Market closed
Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ticker
$OGN
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
10,000
Website
Organon Metrics
BasicAdvanced
$3.6B
4.24
$3.33
0.72
$1.12
7.93%
Price and volume
Market cap
$3.6B
Beta
0.72
52-week high
$23.10
52-week low
$13.87
Average daily volume
3.8M
Dividend rate
$1.12
Financial strength
Current ratio
1.6
Quick ratio
0.797
Long term debt to equity
1,900.847
Total debt to equity
1,774.645
Dividend payout ratio (TTM)
34.38%
Interest coverage (TTM)
2.86%
Management effectiveness
Return on assets (TTM)
7.39%
Return on equity (TTM)
429.85%
Valuation
Price to earnings (TTM)
4.243
Price to revenue (TTM)
0.567
Price to book
7.38
Price to tangible book (TTM)
-0.75
Price to free cash flow (TTM)
6.177
Dividend yield (TTM)
7.93%
Forward dividend yield
7.93%
Growth
Revenue change (TTM)
2.24%
Earnings per share change (TTM)
-16.54%
3-year revenue growth (CAGR)
0.52%
3-year earnings per share growth (CAGR)
-14.40%
3-year dividend per share growth (CAGR)
25.99%
What the Analysts think about Organon
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Organon Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Organon Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Organon News
AllArticlesVideos
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Business Wire·6 days ago
Why Organon Is A Top Pick For Income Investors
Seeking Alpha·2 weeks ago
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $3.6B as of April 03, 2025.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 4.24 as of April 03, 2025.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of April 03, 2025, the dividend rate is $1.12 and the yield is 7.93%. Organon has a payout ratio of 34.38% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment date is unconfirmed.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.